Polomar Health Services, Inc. (PMHS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 1 | - | - |
| Operating profit | $m | -11 | - | ||||||
| Net profit | $m | - | -0 | -0 | -0 | -1 | -11 | - | - |
| EPS reported | $ | -0.39 | - | ||||||
| Operating cashflow per share | $ | -0.01 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -0.01 | - | ||||||
| Free cash flow | $m | -0 | - | ||||||
| Net debt | $m | -0 | - | ||||||
| Book value equity | $m | -1 | - | ||||||
| Book value per share | $ | -0.04 | - | ||||||
| Number of shares | m | 27.76 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -18.17 | - | ||||||
| P/S LTM | x | 34.26 | - | ||||||
| P/FCF LTM | x | -56.08 | - | ||||||
| EV/EBITDA LTM | x | -28.43 | - | ||||||
| EV/Sales LTM | x | 34.08 | - | ||||||
| Earnings Yield LTM | % | -48.19% | - | ||||||
| FCF Yield | % | -1.78% | - | ||||||
| Quality | |||||||||
| ROE | % | +875.47% | - | ||||||
| ROIC | % | +8.74% | - | ||||||
| Operating margin | % | -16.28% | - | ||||||
| Gross margin | % | +70.98% | - | ||||||
| FCF/Sales | % | -61.09% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1001.98% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -26.64 | - | ||||||
| Net Debt/EBITDA | x | 0.15 | - | ||||||
| EBIT/Net interest | x | -69.94 | - | ||||||
| Net debt/market cap | % | +0.07% | - | ||||||
| Net debt/Equity | x | 0.10 | - | ||||||
| Gross debt/equity | x | -0.01 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; and intends to launch PoloMeds for diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker’s nevus, vitiligo, and other common skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; and intends to launch PoloMeds for diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker’s nevus, vitiligo, and other common skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free